SAN DIEGO, Jun 14, 2004 (BUSINESS WIRE) -- Pharmessen Scientific, Inc. (Other OTC:PASC.PK), a global nutraceutical and pharmaceutical research company focused on providing leading supplements and medications for better general health, announced the opening of a liaison office in Hamburg, Germany to be managed by Dr. Manfred Stein DVM MSc PhD. Dr. Stein will serve as the Director of Research and Development and has been appointed to the Board of Directors of Pharmessen's UK company, Pharmessen, Ltd.
"We are fortunate to have Dr. Stein and his team of nutritionists and food chemists supporting existing operations in Germany and developing additional market opportunities throughout Europe," commented Mr. George Macleod, Pharmessen's Chief Executive Officer. "I look forward to immediate and ongoing successes as a result of Dr. Stein's appointment."
Dr. Stein is a leading expert on diet and dietary supplements. He received a doctorate from the Institute of Pharmacology in Hanover, Germany and is a member of the European Institute for Food and Nutrition Science, an independent society of scientists, nutritionists, and physicists. Dr. Stein will be responsible for the overall expansion of Pharmessen's pure, herbal supplements and compounds into mainland Europe, including SLIMTRAX, for weight-management and appetite control; MAXOPLEX, for improved general health; and GOLFOFLEX, for enhanced athletic performance.
About Pharmessen Scientific, Inc.
Pharmessen Scientific, Inc. is a global nutraceutical and pharmaceutical company that was formed to research, develop, produce, and market pure herbal supplements and compounds. At the core of Pharmessen's business are its patented encapsulation technology and "water activation" delay processes, which in combination enable the company's products to benefit from enhanced and extended potency. Utilizing this proprietary blending formula, the company effectively combines herbal oil extracts from organically grown plants to create novel supplements and compounds. Pharmessen is presently developing new anti-microbial and biocide agents in order to improve the treatment of diseases caused by new and multi-resistant pathogens. Additional information can be found on our website, www.pharmessen.com.
Safe Harbor Statement
This release contains forward-looking statements with respect to the results of operations and business of Pharmessen Scientific, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.